DiscoverISTH Podcasts
ISTH Podcasts
Claim Ownership

ISTH Podcasts

Author: International Society on Thrombosis and Haemostasis

Subscribed: 24Played: 311
Share

Description

ISTH is the leading international professional society on thrombosis and hemostasis. Listen to our podcast for the latest educational resources in our field.
84 Episodes
Reverse
In this second installment of the ISTH Pulse Podcast series on next-generation factor VIII mimetics, host Dr. Julia Sandrin Gauer is joined by hemophilia experts Dr. Sanjay Ahuja and Dr. Allison Wheeler to explore the evolving landscape of hemophilia A treatment. The discussion examines practical considerations for transitioning patients to newer therapies, including treatment adherence, laboratory monitoring and individualized care. The experts also address managing breakthrough bleeding, preparing for surgical procedures and improving communication among healthcare providers. Tune in to discover how emerging therapies could help reduce treatment burden and shape the future of hemophilia care. See a full transcript of this episode here: https://bit.ly/3UmJnUE
As the treatment landscape for immune thrombocytopenia (ITP) continues to evolve, emerging therapies are offering new possibilities for patients and clinicians. Global expert Dr. Adam Cuker and patient advocate Cass Benedetto discuss the future of ITP treatment from both clinical and patient perspectives, from emerging therapies and unmet patient needs to individualized treatment decisions and the importance of considering quality of life beyond platelet counts. This episode is supported by Novartis.  See the following links to obtain credits for this CME activity: Syllabus: https://www.francefoundation.com/9499-itp-podcast-cme Podcast evaluation: https://surveys.francefoundation.com/s3/9499-Preparing-for-What-s-Next-for-ITP-Therapies-Enduring-Podcast-Evaluation
What happens when patients become partners in shaping clinical research? In this episode of the ISTH Pulse Podcast, host Dr. Julia Sandrin Gauer is joined by Dr. Sudeep Shivakumar and patient advocate Carol West to explore the role of patient perspectives in the EPCAT III trial, a Canadian-led study examining strategies to prevent venous thromboembolism (VTE) following hip and knee replacement surgery. The discussion highlights the collaboration between the EPCAT III research team and the CanVECTOR Patient Partners Platform, exploring how lived experiences can inform research priorities, trial design and clinical decision-making. Tune in to learn why bringing the patient voice into research matters and how meaningful collaboration can help shape future studies. Read the study here: www.nejm.org/doi/abs/10.1056/NEJMoa2603649?referrer=https%3A%2F%2Fwww.google.com%2F
Women can face unique blood clot risks across different stages of life, from hormonal contraception and pregnancy to the postpartum period and menopause. But there are still gaps in recognition and diganosis. In a special World Thrombosis Day episode of the ISTH Pulse Podcast, host Dr. Geoffrey Barnes is joined by experts Dr. James Douketis and Dr. Angela Weyand to ask an important question: Are we missing the warning signs? Together, they discuss where progress has been made, where gaps remain and what healthcare professionals can do to better recognize and address thrombosis risks in women. The conversation also explores broader challenges in women’s health, opportunities to improve research and clinical care and why this topic is at the center of the World Thrombosis Day campaign. Learn more and find resources at: https://www.worldthrombosisday.org/women-blood-clots/
In episode 3 of this ISTH Pulse Podcast miniseries, experts explore why next-generation mimetic therapies may be needed in hemophilia A and what they could add to an already evolving treatment landscape. The discussion examines how well current prophylactic options control bleeding, where treatment burden and unmet needs remain and whether less-frequent, subcutaneous dosing could support greater treatment convenience, adherence and access. Our experts also considers how factor VIII inhibitor status may influence treatment decisions and which patients could potentially benefit most as new mimetic therapies continue to develop. This episode is supported by an independent medical education grant from Bayer.
loading
Comments